Rezolute, Inc. (NASDAQ: RZLT) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
4.68
-0.01-0.21%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | - | Shs Outstand | 96.29M | Perf Week | -0.64% |
| Market Cap | 451.61M | Forward P/E | - | EPS next Y | -0.33 | Insider Trans | 0.00% | Shs Float | 66.01M | Perf Month | -8.58% |
| Enterprise Value | 441.49M | PEG | - | EPS next Q | -0.13 | Inst Own | - | Short Float | 24.71% | Perf Quarter | 51.78% |
| Income | -75.42M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 8.79 | Perf Half Y | 60.62% |
| Sales | 0.00 | P/B | 4.18 | EPS next Y | 49.71% | ROA | -64.95% | Short Interest | 16.31M | Perf YTD | 98.73% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -58.82% | 52W High | 11.44 -59.08% | Perf Year | -17.57% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -73.68% | 52W Low | 1.07 338.32% | Perf 3Y | 164.97% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 7.05% 7.07% | Perf 5Y | -57.90% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | 30.08% | Oper. Margin | 0.00% | ATR (14) | 0.34 | Perf 10Y | -91.07% |
| Dividend Ex-Date | - | Quick Ratio | 15.84 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 48.04 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 15.84 | EPS Q/Q | 0.00% | SMA20 | -2.54% | Beta | 0.57 | Target Price | 8.67 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | - | SMA50 | 1.01% | Rel Volume | 0.55 | Prev Close | 4.69 |
| Employees | 68 | LT Debt/Eq | 0.01 | Earnings | Sep 16 | SMA200 | 1.65% | Avg Volume | 1.81M | Price | 4.68 |
| IPO Date | Jan 14, 2013 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -17.79% - | Net Debt/EBITDA | 0.12 | Volume | 986,250 | Change | -0.21% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jun-03-26 | Upgrade | Citizens | Market Perform → Market Outperform | |
| Jun-03-26 | Reiterated | Wedbush | Outperform | $2.00 → $6.00 |
| Jun-02-26 | Reiterated | BTIG | Buy | $5.00 → $6.00 |
| May-14-26 | Reiterated | Maxim Group | Buy | $4.00 → $10 |
| Mar-25-26 | Upgrade | Wedbush | Neutral → Outperform | |
| Jan-08-26 | Reiterated | Wedbush | Neutral | $1.00 → $2.00 |
| Dec-12-25 | Reiterated | Maxim Group | Buy | $4.00 |
| Dec-12-25 | Reiterated | HC Wainwright & Co. | Buy | $14 → $5.00 |
| Dec-11-25 | Reiterated | Craig-Hallum | $14 → $2.00 | |
| Dec-11-25 | Reiterated | BTIG | Buy | $17 → $5.00 |
Latest News
Jul-21-26
Jul-21-2607:30AM
Rezolute to Participate in the BTIG Virtual Biotechnology Conferenceglobenewswire.com
Jun-17-26
Jun-17-2607:15AM
Jun-15-26
Company
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 6/30/2025 | FY 2024 6/30/2024 | FY 2023 6/30/2023 | FY 2022 6/30/2022 | FY 2021 6/30/2021 | FY 2020 6/30/2020 | FY 2019 6/30/2019 | FY 2018 6/30/2018 | FY 2017 6/30/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 18 | 15 | 12 | — | — | — | — | — | — | |
| Research and Development | 62 | 56 | 44 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | -1 | 0 | — | — | — | — | — | — | |
| Operating Income | -80 | -70 | -56 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 5 | 2 | 4 | — | — | — | — | — | — | |
| Net Income Before Taxes | -74 | -68 | -52 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -74 | -68 | -52 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -74 | -68 | -52 | — | — | — | — | — | — | |
| Net Income | -74 | -68 | -52 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.98 | -1.33 | -1.01 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.98 | -1.33 | -1.01 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.98 | -1.33 | -1.01 | — | — | — | — | — | — | |
| EBITDA | -74 | -68 | -52 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 76 | 51 | 51 | — | — | — | — | — | — | |
| Market Capitalization | 339 | 219 | 101 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Evans Daron | CFO | Mar 30 '26 | Buy | 2.85 | 10,000 | 28,500 | 414,462 | Mar 31 |
| Hogenhuis Wladimir | Director | Dec 16 '25 | Buy | 1.69 | 5,650 | 9,549 | 119,675 | Dec 17 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer | Dec 16 '25 | Buy | 1.70 | 28,000 | 47,600 | 308,352 | Dec 17 |
| Evans Daron | CFO | Dec 15 '25 | Buy | 1.77 | 45,000 | 79,578 | 415,900 | Dec 15 |
| Elam Nevan C | CEO | Dec 15 '25 | Buy | 1.59 | 32,000 | 50,880 | 641,119 | Dec 15 |
| Karnawat Sunil Ratilal | Chief Commercial Officer | Dec 15 '25 | Buy | 1.62 | 12,100 | 19,599 | 71,542 | Dec 15 |
| ROBERTS BRIAN KENNETH | Chief Medical Officer | Jun 25 '25 | Buy | 4.38 | 2,500 | 10,939 | 15,500 | Jun 26 |
| Evans Daron | CFO | Jun 24 '25 | Buy | 4.05 | 5,000 | 20,250 | 268,900 | Jun 24 |
| Kim Young-Jin | Director | Jun 13 '25 | Buy | 3.25 | 1,230,769 | 3,999,999 | 8,423,386 | Jun 23 |
| KREHER NERISSA | Director | Jun 13 '25 | Buy | 3.25 | 3,076 | 9,997 | 37,576 | Jun 23 |
| Hogenhuis Wladimir | Director | Mar 31 '25 | Buy | 2.92 | 6,758 | 19,733 | 84,025 | Apr 01 |
| Elam Nevan C | CEO | Mar 27 '25 | Buy | 2.85 | 12,302 | 34,999 | 224,119 | Mar 31 |
| Evans Daron | CFO | Mar 26 '25 | Buy | 2.88 | 20,000 | 57,700 | 237,900 | Mar 28 |
| Hogenhuis Wladimir | Director | Feb 18 '25 | Buy | 4.70 | 10,000 | 47,000 | 77,267 | Feb 20 |
| Kim Young-Jin | Director | Jun 25 '24 | Buy | 4.00 | 1,250,000 | 5,000,000 | 7,192,617 | Feb 19 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.